Pancreatic cancer is typically diagnosed through a combination of imaging scans, blood tests, and tissue biopsy, often after symptoms like unexplained weight loss, jaundice, or new-onset diabetes prompt a medical workup. Because the pancreas sits deep in the abdomen behind other organs, there is no single quick test. Instead, diagnosis unfolds in stages: detecting a suspicious mass, confirming it with tissue sampling, and then determining how far it has spread.
Symptoms That Trigger the Workup
Most people don’t have symptoms in the earliest stages, which is a major reason pancreatic cancer is so often caught late. When symptoms do appear, the most common ones include loss of appetite, unexplained weight loss, and jaundice (yellowing of the skin and whites of the eyes). Jaundice happens when a tumor blocks the bile duct, and it often shows up without any belly pain. You may also notice dark urine and pale stools.
A new diabetes diagnosis, or existing diabetes that suddenly becomes harder to control, can also be an early signal. This happens because the pancreas produces insulin, and a growing tumor can disrupt that function. None of these symptoms are unique to pancreatic cancer, but when several appear together, or when jaundice develops without an obvious cause, doctors move quickly to imaging.
CT Scans: The First-Line Imaging Test
A specialized CT scan called a pancreatic protocol CT is the standard first step. It takes images during two specific phases of blood flow through the abdomen, which makes pancreatic tumors easier to spot against surrounding tissue. This scan is about 90% sensitive and 99% specific for detecting solid pancreatic tumors, meaning it catches the vast majority of masses and rarely flags something that isn’t there.
The major limitation is size. For tumors smaller than 2 centimeters, sensitivity drops to around 77%. That gap matters because smaller tumors are more likely to be surgically removable. On imaging, a typical pancreatic cancer appears as a mass with poor blood supply, often accompanied by a dilated pancreatic duct upstream of the tumor, shrinkage of the downstream pancreas, and sometimes visible involvement of nearby blood vessels.
When MRI Adds Clarity
MRI is not usually the first test ordered, but it plays an important role when CT results are unclear or when a patient can’t receive the contrast dye used in CT scanning. MRI has roughly equal sensitivity to CT for assessing how far a tumor has spread locally. A technique called diffusion-weighted MRI has shown particular promise for picking up early-stage lesions and may eventually be used more routinely.
MRI is also valuable for distinguishing pancreatic cancer from conditions that can look similar on imaging, such as chronic pancreatitis or autoimmune pancreatitis. These lookalikes can form mass-like areas in the pancreas that mimic cancer on a CT scan. Specific MRI features help tell them apart. For instance, in autoimmune pancreatitis, the pancreatic duct narrows gradually (sometimes called the “icicle sign”), while in cancer, the duct tends to cut off abruptly. Kidney abnormalities visible on MRI can also point toward autoimmune pancreatitis rather than cancer.
The CA 19-9 Blood Test
CA 19-9 is a protein that pancreatic cancer cells often release into the bloodstream. A blood test for this marker is commonly ordered during the diagnostic process, but it has important limitations. Elevated CA 19-9 levels can also result from bile duct blockage, liver disease, pancreatitis, and other non-cancerous conditions. It is not reliable enough to diagnose pancreatic cancer on its own.
Some people simply don’t produce CA 19-9 at all, even when they have a cancer that would normally raise levels of this protein. For those individuals, the test provides no useful information. Where CA 19-9 proves most helpful is after diagnosis: tracking levels over time to gauge whether treatment is working or whether the cancer has returned.
Endoscopic Ultrasound and Biopsy
To confirm a diagnosis, doctors need a tissue sample. The preferred method is endoscopic ultrasound-guided biopsy, often abbreviated EUS-FNA. During this procedure, a thin, flexible scope is passed through your mouth and into your stomach or small intestine, where an ultrasound probe on the tip produces close-range images of the pancreas. A fine needle is then guided through the scope wall directly into the mass to collect cells.
This approach has a diagnostic accuracy ranging from about 73% to 90%, with a pooled sensitivity around 81% and specificity of roughly 96%. In practical terms, when the biopsy confirms cancer, you can be very confident in that result. A negative biopsy is less definitive, and a repeat procedure or alternative approach may be needed if suspicion remains high.
EUS-guided biopsy has a complication rate of just 1 to 2%, making it considerably safer than biopsies performed through the skin with a needle guided by CT. Serious complications like significant bleeding or infection are rare, occurring in well under 1% of procedures. Endoscopic ultrasound also has a notable advantage in detecting very small lesions. In one comparison study, EUS detected pancreatic abnormalities in 42% of screened individuals, compared to 35% for MRI and just 11% for CT, with average detected lesion size of only about half a centimeter.
Determining Resectability
Once pancreatic cancer is confirmed, the most critical staging question is whether the tumor can be surgically removed. Surgery offers the only realistic chance of long-term survival, but only about 15 to 20% of patients are candidates at diagnosis. Staging revolves around the tumor’s relationship to nearby major blood vessels.
Tumors are classified into three categories. Resectable tumors have clear separation from the major arteries and veins near the pancreas. Borderline resectable tumors touch or partially involve certain blood vessels but may become operable after a course of chemotherapy. Locally advanced tumors have wrapped around critical arteries to a degree that makes safe surgical removal unlikely. Complete encasement of one particular artery (the superior mesenteric artery) is generally considered a point of no return for surgery, while encasement of another (the celiac artery) may still allow surgical consideration after treatment shrinks the tumor.
This classification is determined primarily from the pancreatic protocol CT scan, sometimes supplemented by MRI or diagnostic laparoscopy (a small camera inserted through the abdomen to look for spread that imaging may have missed).
Screening for High-Risk Individuals
For the general population, there is no recommended routine screening test for pancreatic cancer. But people at elevated risk can benefit from surveillance. This includes individuals with inherited genetic changes linked to higher pancreatic cancer risk, those with multiple family members who have had the disease, and people with chronic pancreatitis or certain new-onset diabetes patterns.
Surveillance programs typically use a combination of MRI and endoscopic ultrasound, alternating every six to twelve months. Research from the National Cancer Institute suggests that this approach can catch cancers at earlier, more treatable stages in high-risk groups. A blood-based liquid biopsy test has shown early promise for detecting pancreatic cancer from a simple blood draw, but it has not yet been validated in the large-scale trials needed before it can be used clinically. Experts believe its most practical initial use would be in these same high-risk populations rather than as a screening tool for everyone.